Company newsMRNA
Explain this story: Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of "Hold" from Analysts
Moderna, Inc. (NASDAQ:MRNA) has received a consensus "Hold" recommendation from analysts, with four suggesting a sell, thirteen a hold, and seven a buy. The average 12-month price target is significantly lower than its current share price, yet the company reported better-than-expected quarterly revenue and a slightly narrower loss per share. While its mRNA pipeline shows promise, insider selling and a high valuation pose potential risks.
OtherMarketBeatSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Moderna, Inc. (NASDAQ:MRNA) has received a consensus "Hold" recommendation from analysts, with four suggesting a sell, thirteen a hold, and seven a buy. The average 12-month price target is significantly lower than its current share price, yet the company reported better-than-expected quarterly revenue and a slightly narrower loss per share. While its mRNA pipeline shows promise, insider selling and a high valuation pose potential risks.
Article tone: Neutral This describes the words the journalist used. It is not a prediction, and not advice.
Published Sep 25, 2026, 03:13 ET · on this site +1d 22h